Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | microtubule associated protein 2 | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Echinococcus multilocularis | tumor protein p63 | Get druggable targets OG5_140038 | All targets in OG5_140038 |
Schistosoma japonicum | ko:K04380 microtubule-associated protein tau, putative | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Echinococcus granulosus | microtubule associated protein 2 | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Schistosoma mansoni | microtubule-associated protein tau | Get druggable targets OG5_133504 | All targets in OG5_133504 |
Echinococcus granulosus | tumor protein p63 | Get druggable targets OG5_140038 | All targets in OG5_140038 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | tumor protein p63 | 0.0408 | 0.2752 | 0.0259 |
Loa Loa (eye worm) | hypothetical protein | 0.047 | 0.3808 | 1 |
Brugia malayi | Muscle positioning protein 4 | 0.047 | 0.3808 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0397 | 0.256 | 0.5 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0397 | 0.256 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0425 | 0.3042 | 0.7986 |
Leishmania major | hypothetical protein, conserved | 0.0397 | 0.256 | 0.5 |
Brugia malayi | SEA domain containing protein | 0.0425 | 0.3042 | 0.3858 |
Onchocerca volvulus | 0.0425 | 0.3042 | 0.3858 | |
Onchocerca volvulus | 0.0425 | 0.3042 | 0.3858 | |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0397 | 0.256 | 0.6722 |
Schistosoma mansoni | hypothetical protein | 0.0425 | 0.3042 | 0.2934 |
Toxoplasma gondii | kringle domain-containing protein | 0.0397 | 0.256 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0397 | 0.256 | 0.6722 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 1 | 1 |
Onchocerca volvulus | 0.047 | 0.3808 | 1 | |
Schistosoma mansoni | hypothetical protein | 0.0397 | 0.256 | 0.2445 |
Echinococcus granulosus | tumor protein p63 | 0.0408 | 0.2752 | 0.0259 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0425 | 0.3042 | 0.7986 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0397 | 0.256 | 0.5 |
Onchocerca volvulus | 0.0425 | 0.3042 | 0.3858 | |
Onchocerca volvulus | 0.0425 | 0.3042 | 0.3858 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 11.2202 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature. (Class of assay: confirmatory) [Related pubchem assays: 902 ] | ChEMBL. | No reference |
Potency (binding) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.